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Oxy-hydrogen Gas: The Rationale Behind Its Use  
as a Novel and Sustainable Treatment for  
COVID-19 and Other Respiratory Diseases 
Abstract
Oxy-hydrogen gas (HHO) is a gaseous mixture of molecular hydrogen and molecular oxygen that is 
generated by the electrolysis of water and delivered in a 2:1 ratio (66% and 33%, respectively) through 
the use of noninvasive inhalation devices such as nasal cannulas or nebulisers. Although there is a 
paucity of scientific evidence supporting this new and emerging therapy, initial investigations indicate 
that HHO proffers cytoprotective qualities, typically by reducing oxidative stress and attenuating 
the inflammatory response. These aspects are particularly favourable when considering respiratory 
medicine because underlying inflammation is known to drive the pathological progress of numerous 
respiratory conditions, including asthma, chronic obstructive pulmonary disorder, and, pertinently, 
coronavirus disease (COVID-19). Direct delivery to the lung parenchyma is also likely to increase the 
effectiveness of this emerging medical therapy. 
This narrative review aims to delineate how this particular combination of gases can affect cellular 
processes at the molecular level by focussing on the evolutionary requirement for both oxygen and 
hydrogen. Furthermore, the authors assess the current available data for the safety and efficacy of 
HHO in a clinical setting. 
INTRODUCTION
During both acute and chronic respiratory 
conditions, including severe coronavirus disease 
(COVID-19) infection, the primary physiological 
response is to synthesise distress proteins, which 
include cytokines, chemokines, and growth 
factors. This phenomenon is known as the 
cytokine storm, an event which can exacerbate 
the inflammatory response and rapidly increase 
the host’s temperature in an attempt to eradicate 
pathogens.1 Such proinflammatory mediators 
increase the production of reactive oxygen 
species (ROS) both within the mitochondrial 
electron transport chain (ETC) and within 
recruited immune cells, such as neutrophils and 
macrophages,2 by the activation of enzymes 
such as NADPH oxidases. 
Authors: Grace Russell,1 *Alexander Nenov,2 John T. Hancock1 
1. Department of Applied Sciences, University of the West of England, Bristol, UK
2. Water Fuel Engineering, Liquorice Way, Pontefract, UK
*Correspondence to Grace2.Russell@live.uwe.ac.uk 
Disclosure: Dr Nenov is a board member of Water Fuel Engineering. The remaining authors have 
declared no conflicts of interest.
Received: 03.02.21
Accepted: 16.03.21
Keywords: Asthma, chronic obstructive pulmonary disorder (COPD), coronavirus disease 
(COVID-19), oxy-hydrogen (HHO), respiratory disease.
Citation: EMJ. 2021; DOI/10.33590/emj/21-00027.
Creative Commons Attribution-Non Commercial 4.0 May 2021  • RESPIRATORY
Mitochondrial dysfunction often occurs when 
cellular demand for the high-energy phosphate 
molecule ATP increases during times of cellular 
stress.3 This situation can lead to congestion in 
the flow of electrons within the ETC, resulting in 
excessive leakage of electrons. Rogue electrons 
are free to combine with molecular oxygen at will, 
forming free radicals including the superoxide 
anion, which dismutates to hydrogen peroxide. 
The reaction within the immune response cells, 
however, is entirely different. The mitochondrial 
content within these cells is considerably 
lower than in somatic cells, and therefore 
is not a significant source of ROS. Instead, 
granulocytes utilise NADPH oxidase enzymes 
to produce a highly oxidative respiratory burst 
containing a myriad of ROS,4 which can include 
superoxide anions, hydrogen peroxide, hydroxyl 
radicals (in the presence of iron [Fe] ions), and 
hypochlorous acid, the latter through the action 
of myeloperoxidase. Mounting evidence suggests 
this is important when considering respiratory 
medicine because elevated levels of granulocytic 
cells are often observed in the bronchoalveolar 
lavage fluid of patients with astringent 
pulmonary diseases.5,6
ROS delivered by such granulocytes can be 
extremely damaging to biomolecules, including 
proteins, carbohydrates, lipids, and nucleotides, 
with intense and acute elevation of ROS 
consistent with acute and chronic inflammatory 
conditions.7 Within the delicate parenchymal 
tissue, such assault often induces degeneration 
of epithelial cells, producing hyalin fluid. This 
process is known to contribute significantly to 
cellular hyperplasia and reduce the capacity 
for oxygen exchange. Raised ROS levels can 
also directly modify DNA nucleotides, affecting 
genetic transcription, and form adducts upon 
essential epigenetic and metabolic enzymes.8-10 
Such post-translational oxidative modifications 
to either nucleotides or proteinaceous enzymes 
often lead to aberrant enzymatic activity, 
causing fluctuation of essential energy-
producing processes and affecting mitochondrial 
function, as well as influencing genetic 
transcription events.
HHO is an emerging medical gas, generated 
from the electrolysis of water. HHO inhalation is 
a noninvasive therapy done via a nasal cannula or 
mask, allowing the gas mixture to directly enter 
the respiratory system. In addition to oxygen 
delivery, HHO also provides molecular hydrogen 
(H2) promptly to the lung parenchyma, the target 
tissue for respiratory infections. Research into 
H2 therapy is rapidly gathering momentum and 
studies have identified H2 as having antioxidant 
scavenging properties,11,12 neutralising the 
deleterious hydroxyl radical and peroxynitrite 
ion. Presumably, other modes of action of H2 are 
also important as the reaction kinetics between 
H2 and these respective biomolecules remain 
in question.13
Despite research into the efficacy of HHO 
therapy still being in its infancy, HHO inhalation 
has been recommended by the Chinese 
government as a treatment of nosocomial 
COVID-19 symptomology.14
AIMS
As the global COVID-19 pandemic threatens 
both individual health and healthcare systems 
globally, and, as yet, there is little effective 
treatment for this novel disease, this review aims 
to explain the HHO generation process and the 
molecular benefits of combining oxygen and 
hydrogen inhalation therapy for COVID-19 and 
other inflammatory respiratory conditions. The 
authors have collated data from empirical and 
evolutionary studies and in-human clinical trials 
and offer an explanation as to how the molecular 
mechanisms behind HHO therapy may be 
beneficial for respiratory health.
DISCUSSION
Generation, Delivery, and Safety Profile 
of Oxy-hydrogen 
HHO is a stoichiometric mixture of H2 (66%) and 
O2 (33%) obtained through the electrolysis of 
water (H2O). As pure water has a low electrical 
conductivity and requires an excess of energy 
to degrade the hydrogen bonds that hold the 
molecule together, it is therefore necessary to 
add a water-soluble electrocatalyst (e.g., K+, Mg2+, 
or Na+) to reduce the activation threshold.15 HHO 
gas can be easily generated by adding electrolyte 
compounds, such as sodium or potassium 
hydroxides, to distilled water and applying a 
low-voltage (9–13 V) direct current.16 The O2 and 
H2 would collect in the gas phase as the water 
would become rapidly saturated and gases such 
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as H2 have a relatively low solubility, as discussed 
by Hancock et al.17
In its simplest form, an electrolyser cell contains 
two electrodes, the positive cathode and a 
negative anode, separated by an ion exchange 
membrane. Passing an electrical current through 
the water decomposes H2O into H
+ and OH- 
ions. These electrophilically charged molecules 
are then attracted to the opposingly charged 
electrode where they liberate as gases. The 
chemical activity at the anode is 2H2O  O2 + 4H
+ 
+ 4e- whilst the activity at the cathode equates to 
4H+ + 4e-  2H2. This method ensures separation 
utilising the 2H2O  2H2 + O2 reaction without 
returning it to the aqueous state. 
As interest grows in this particular field 
of research, the industry surrounding the 
development of HHO products is also expanding. 
An HHO generator's standard specification 
incorporates an electrolysis unit, a filter, and 
an electronic control unit. The control unit can 
adjust the voltage directed to the positive and 
negative plates. Once formed, HHO can enter the 
respiratory system directly by inhalation through 
either a nasal cannula or an inhalation mask at a 
peak rate of 2–3 L/min. Gas inhalation through 
nasal cannulas is a safe and noninvasive delivery 
method widely used globally for pure oxygen 
inhalation within healthcare settings.
Although being comprised of the highly 
flammable gases hydrogen and oxygen, known 
to reduce the combustion threshold for most 
substances, the safety profile of HHO in a 
clinical setting can be regarded as favourable. 
This is partly because of the high autoignition 
threshold of HHO (570 οC),18 the contained 
generation within a sealed system, and because 
HHO typically gets used as generated. Although 
the likelihood of explosion when using an HHO-
generation device is negligible, consideration 
over the combustion potential in the presence 
of a naked flame is warranted; consequently, 
activities that involve use of a flame, including 
smoking, during treatment pose a significant risk 
of igniting HHO and causing potential harm.
The Requirement for Oxygen
Rapid oxygenation of the Earth’s atmosphere, 
known as the Great Oxygen Event, took place 
approximately 2 billion years ago during the 
early Paleoproterozoic era.19 It is assumed that 
this event was triggered by photosynthesising 
cyanobacteria that produced oxygen as a waste 
product.20 As the rapid rise in atmospheric O2 
presented a new challenge for cellular energetics, 
single-celled life forms were forced to adapt, 
including giving rise to multicellular life.
On a cellular level, O2 is integral to the process of 
energy generation during aerobic respiration. The 
cardinal role here is for oxygen to act as a terminal 
electron acceptor during aerobic respiration.21 
Aerobic respiration is the biochemical process of 
ATP synthesis that occurs in the mitochondria. 
ATP synthesis is crucial to all cellular processes 
as it is a high-energy molecule responsible for 
donating energetic phosphate moieties during 
cellular metabolic pathways. 
With eight electrons and eight protons in each 
molecule, O2 is an electrophilically neutral 
diradical compound with two unpaired electrons 
in its outer shell. This neutrality allows the O2 
molecule to easily diffuse through cellular 
membranes and into the mitochondria where 
it is required to accept electrons donated 
by complex IV (cytochrome oxidase) in the 
ETC. If oxygen is not present to fulfil this role, 
aerobic respiration, responsible for producing 
a theoretical 38 ATP per glucose molecule, 
discontinues and the less efficient anaerobic 
respiratory pathway is initiated, generating a 
mere two ATP per glucose molecule.22 Prolonged 
anaerobic activity is unsustainable in higher life 
forms as the energy produced is insufficient to 
sustain essential cellular functions. Granulocytic 
leukocyte cells, such as neutrophils, rely much 
more on glycolytic production of ATP because 
of a lack of mitochondrial presence in these 
specific cells,23,24 a factor that allows these cells 
to continue functioning even during hypoxaemia 
where oxygen supply is notably reduced. 
As described above, oxygen is fundamental to 
the survival of higher organisms and the average 
adult (63 kg) consumes approximately 200 mL 
of O2 every minute at standard temperature 
and pressure,25 equating to 400 L per day. 
Once O2 is inhaled into the lungs from the 
atmosphere, it is exchanged for CO2 as O2 has 
a higher binding affinity with iron-containing 
haemoglobin in red blood cells. Healthy 
saturation of haemoglobin, a measurement of 
the percentage of haemoglobin molecules that 
carry O2, is between 94% and 98%.
26 Saturation 
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levels below this threshold typically lead to 
hypoxaemia, which if unrectified can lead to 
hypoxia: a condition where tissues do not receive 
adequate amounts of O2. This situation can 
progress to acute respiratory distress syndrome, 
multiple organ failure, and potentially death if 
left untreated.
Estimated oxygen usage in ambulances in the UK 
is reported to be in excess of 2 million times each 
year, equating to 34% of attended call-outs.26,27 In 
these cases, O2 therapy is not typically used to 
alleviate the symptoms of respiratory distress; 
instead, it is often used to prevent hypoxaemia 
in emergency conditions, including cardiac arrest 
and trauma. Oxygen is given to approximately 
one in five patients in nosocomial care.27 In this 
setting, O2 inhalation is prescribed for a vast array 
of life-threatening conditions, including those that 
cause a rapid onset of depressed breathing, such 
as anaphylaxis, COVID-19, opioid overdose, and 
pneumonia, as well as for persistent hypoxaemic 
complaints. By providing O2 therapy, clinicians 
are able to increase oxygen tension in the alveoli 
during such events, thereby decreasing the 
respiratory system’s workload by fulfilling the 
cellular demand for O2.
28 Although widely used 
in emergency medicine, it is important to note 
that oxygen is also prescribed for the alleviation 
of chronic respiratory complaints such as asthma, 
chronic obstructive pulmonary disorder (COPD), 
cystic fibrosis, and paediatric respiratory disease.
The Requirement for  
Molecular Hydrogen
As the most basic element within the universe, it 
may come as no surprise that molecular hydrogen 
has played a pivotal role in the evolutionary 
process. One intriguing theory, highlighted 
by Andersson and Kurland,29 implies that the 
bacterial endosymbiont's original function was to 
provide the host cell with H2. 
The hydrogen hypothesis advocates for an 
archaeon host cell with a facultative anaerobic 
means of respiration, making use of CO2 as a 
metabolic substrate and producing H2 as a by-
product, instead of being a committed aerobe 
with an immediate demand for ATP as suggested 
in the traditional endosymbiotic theory.29 
Indeed, the last universal common ancestor 
has been described as having all enzymes 
associated with both mitochondria responsible 
for ATP production in aerobic organisms, and 
hydrogenosomes that facilitate metabolic 
processes in anaerobic organisms. Their later 
divergence can be explained by environmental 
pressures that ultimately led to natural 
selection events. 
Although this debate has yet to be rectified, it 
has raised some thought-provoking questions 
worthy of further exploration. When considering 
the hydrogen hypothesis, of particular 
appeal is the homologous protein expression 
profile noted within both mitochondria and 
hydrogenosomes.30 Despite both organelles 
differing in their biochemical activities, they each 
have the capacity to encode for proteins of both 
complex I and II of the ETC. However, it is only 
the mitochondrial genome that can encode for 
elements of complexes III–IV and, importantly, 
ATP synthase. If, as suggested by Lewis et al.31 and 
others,32,33 hydrogenosomes and mitochondria 
are delineated from the same original symbiont, 
it is likely that mitochondria once had the ability 
to produce H2.
Yet another link to the evolutionary requirement 
for H2 in eukaryotes are the hydrogenase enzymes 
found in many species of photosynthesising 
organisms, including algae and higher plants. 
To exemplify, the single-celled green alga 
Chlamydomonas reinhardtii contains two 
Fe- hydrogenases (HYDA1 and HYDA2) that 
can receive electrons from ferredoxin during 
photosynthesis,34 reducing proton accumulation 
with the reaction 2H+ + 2e-  H2. Furthermore, 
homologous hydrogenase enzymes are also 
found in higher plants, including crops such as 
the legume Medicago truncatula35 and Oryza 
sativa subsp. japonica (rice).36 The frequency 
and diversity with which hydrogen-producing 
mechanisms have occurred along the phylogenic 
tree suggest an inherent biological requirement 
for H2 across all domains of life.
In addition to the activity of hydrogen-producing 
enzymes and organelles in eukaryotic species, 
many anaerobic bacteria metabolise H2. Typically, 
bacterial generation of hydrogen is linked with 
transition metal-containing (e.g., nickle/iron 
[NiFe] or iron/iron [FeFe]) hydrogenase enzymes 
that catalyse the reversible oxidation of hydrogen 
with the reaction 2H+ + 2e-  2H2.
37 Interestingly, 
hydrogen-producing bacteria are known to form 
symbiotic relationships with both plants and 
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animal species, which may also fulfil the cellular 
requirement for H2 in multicellular organisms, 
including humans. Here, H2 is largely obtained 
from the symbiotic relationship between H2-
producing intestinal microflora (e.g., Escherichia 
coli or Clostridium butyricum) and the host.38
Aside from the largely theoretical requirement for 
H2 in the early development of life, contemporary 
research is beginning to reveal that molecular 
hydrogen can act as a natural antioxidant in at 
least two possible ways: 1) through the selective 
scavenging of nonsignalling ROS/reactive 
nitrogen species, such as the hydroxyl radical 
and peroxynitrite, thus potentially reducing 
oxidative damage to cellular membranes and 
the inactivation of metabolic enzymes through 
oxidative post-translational modifications.39 It 
should be made clear that the reaction kinetics 
here are unfavourable13 and more research is 
needed before these claims can be verified 
and universally accepted; and, 2) via increased 
activity of nuclear factor erythroid 2–related 
factor 2 (Nrf2), a transcription factor responsible 
for upregulating the activity of the antioxidant 
response element, a cis-acting enhancer 
sequence located within the promotor region of 
more than 200 genes known to transcribe and 
translate antioxidant enzymes (e.g., catalase 
and superoxide dismutase) and cytoprotective 
proteins and peptides (e.g., glutathione-S-
transferase and cytochrome P450 isoenzymes).40 
In addition to the antioxidant effect H2 clearly 
provides, there is also a wealth of laboratory 
evidence that describes H2 as having both 
immunomodulatory and antiapoptotic effects 
in various plant and animal species. This may 
be largely attributed to increased activity of 
Nrf2.41 To illustrate, increased Nrf2 activity has 
been demonstrated to causally undermine 
expression profiles of NF-κB,42 a transcription 
factor associated with innate immunity and one 
responsible for promoting genetic transcription 
of numerous proinflammatory molecules.43 As 
well as downregulating the proinflammatory 
response at the genetic level, Nrf2 is known to 
respond to and upregulate expression of haem 
oxygenase, an enzyme that has a canonical 
function in reducing and preventing vascular 
inflammation.44 Also of interest, particularly 
when considering the broader immune response, 
is the influence of NF-κB on adaptive immune 
cells. Here, NF-κB can provoke and stimulate 
inflammatory T-cell differentiation.45,46 Therefore, 
enhancing or even prolonging the activity of Nrf2 
within the nucleus is likely to have a significant 
effect on the inflammatory profile during disease. 
The Benefits of Oxy-hydrogen in 
Respiratory Medicine
Although, as previously stated, research into the 
benefits of HHO as a medical gas is at an early 
stage, the recent pandemic concerning the 
severe acute respiratory syndrome coronavirus 
2 (SARS-CoV-2) has highlighted the need for 
emergency respiratory care that is effective in 
reducing parenchymal inflammation. This need 
becomes of particular relevance as inflammatory 
exudate is known to contribute to the impairment 
of the alveoli's oxygen-exchange capacity, 
further exacerbating hypoxaemic conditions 
during severe infection. In a recent study 
involving murine models of asthma conducted 
by Zhang et al.,47 1 hour of HHO inhalation per 
day was demonstrated to decrease airway 
resistance and reduce epithelial cell hyperplasia. 
Furthermore, significant reductions in the 
expression of proinflammatory mediators were 
identified, including chemokines (e.g., CXCL15), 
cytokines (e.g., TNF-α), and multiple interleukins 
(e.g., IL-4 and IL-6).47 These findings may prove 
to be particularly relevant as tocilizumab, an 
IL-6 intervention therapy, is currently being 
used to treat COVID-19 as well as autoimmune 
and other severe inflammatory conditions.48 
However, the benefits of this treatment may 
be outweighed by the possible side effects, 
which include an increased occurrence of upper 
respiratory tract infections, hypertension, and 
gastrointestinal perforation.49
Despite the growing popularity of HHO as a 
potential medical therapeutic, there is, as yet, 
sparse evidence on the clinical safety of using 
HHO generators; however, initial in-human trials 
into the effects of HHO in patients with tracheal 
stenosis reported no adverse effects of treatment 
(n=35).50 Additionally, trials into the effects of 
HHO supplementation during severe COVID-19 
infection are ongoing in the Hubei province of 
the People’s Republic of China,51 with Chinese 
health officials recommending HHO therapy in 
the national treatment protocol for coronavirus-
associated pneumonia.14
Creative Commons Attribution-Non Commercial 4.0 May 2021  • RESPIRATORY
Additionally, during a 3-month, in-human 
trial assessing the safety and efficacy of HHO 
inhalation therapy, a curative effect was noticed 
from the second week until the end of the trial 
in patients (n=70) with severe COPD.52 These 
findings are further supported by results from 
a 10-day, multi-centre, randomised, double-
blind study that reported easement of COPD 
symptoms on observing days 1–7 (n=54).53 
Similar findings have also been reported in 
studies of chronic inflammatory respiratory 
diseases, including asthma, cystic fibrosis,54 and 
COVID-19.55 Here, increased oxygenation and the 
cellular protective effects of molecular hydrogen 
has been shown to recover poor blood saturation 
levels of O2 and reduce the inflammatory 
response, thus preventing and rectifying 
hypoxaemia and reducing the likelihood of Type 1 
respiratory failure.57
Future Perspectives
Research into the biochemical properties of 
medical gases is beginning to reveal that, 
alongside O2, H2 may also be of evolutionary 
significance, perhaps by acting as part of the 
suite of gaseous signalling molecules. However, 
laboratory trials utilising human-derived cell 
cultures and animal models will be necessary 
if the molecular mechanisms that influence 
somatic responses are to be elucidated. In 
silico models of distribution patterns, reaction 
kinetics, and longevity will also be required if a 
full understanding of signalling behaviours is to 
be reached. Furthermore, as much of the clinical 
data available have yet to be substantiated, 
data obtained from patient trials will need to be 
hastened if HHO therapy is to be widely used as a 
treatment in general medicine.
CONCLUSION
HHO treatments become of particular relevance 
when considering the increasing occurrence of 
highly contagious and novel viruses; therefore, 
there is an urgent need for sustainable and 
effective treatment protocols that can alleviate 
the most severe symptoms of such respiratory 
tract infections without the need for critical care. 
Emerging clinical and preclinical54,55 data suggest 
that HHO inhalation is both safe and efficacious 
in treating inflammatory-related pulmonary 
disorders. Interestingly, despite objective 
research into the efficacy of HHO therapy being 
relatively new, initial findings suggest inhalation 
of these gases in stoichiometric proportions can 
provide symptomatic relief from chronic and 
acute respiratory conditions, with asthma, COPD, 
and cystic fibrosis being examples. Therefore, it is 
conceivable that combining oxygen, a substance 
known to alleviate respiratory distress by 
increasing alveolar oxygen tension and improving 
O2 saturation of haemoglobin, with hydrogen, 
an element that displays anti-inflammatory and 
antioxidant qualities, in analeptic doses reduces 
the significant burden on lung parenchyma 
during disease. In order to confirm the data 
generated by preliminary investigations into 
HHO inhalation, further clinical, preclinical, and 
laboratory analysis is necessary.
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